StemCell Therapy

Privately-held UK-based company Mogrify and Japanese drugmaker Astellas (TYO: 4503) have signed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.

Using Mogrifys proprietary direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells.

As part of the

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user pleaselogin. If your trial has come to an end, you cansubscribe here.

Try before you buy

All the news that moves the needle in pharma and biotech. Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters. Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. Daily roundup of key events in pharma and biotech. Monthly in-depth briefings on Boardroom appointments and M&A news. Choose from a cost-effective annual package or a flexible monthly subscription.

View post:
Mogrify and Astellas link up on regenerative medicine approaches in sensorineural hearing loss - The Pharma Letter

This entry was posted on July 8, 2022 at 10:13 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |